nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—Crohn's disease	0.345	0.678	CbGaD
Pomalidomide—PTGS2—Crohn's disease	0.164	0.322	CbGaD
Pomalidomide—PTGS2—Balsalazide—Crohn's disease	0.158	0.411	CbGbCtD
Pomalidomide—PTGS2—Mesalazine—Crohn's disease	0.126	0.328	CbGbCtD
Pomalidomide—PTGS2—Sulfasalazine—Crohn's disease	0.0705	0.183	CbGbCtD
Pomalidomide—ABCB1—Prednisone—Crohn's disease	0.0186	0.0484	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—Crohn's disease	0.0111	0.029	CbGbCtD
Pomalidomide—Lenalidomide—TNFSF11—Crohn's disease	0.00528	0.782	CrCbGaD
Pomalidomide—Platelet count decreased—Mesalazine—Crohn's disease	0.00105	0.0229	CcSEcCtD
Pomalidomide—Sepsis—Mercaptopurine—Crohn's disease	0.000999	0.0218	CcSEcCtD
Pomalidomide—Interstitial lung disease—Azathioprine—Crohn's disease	0.000969	0.0211	CcSEcCtD
Pomalidomide—Interstitial lung disease—Mesalazine—Crohn's disease	0.000883	0.0192	CcSEcCtD
Pomalidomide—Breast disorder—Mercaptopurine—Crohn's disease	0.000755	0.0165	CcSEcCtD
Pomalidomide—Pancytopenia—Mercaptopurine—Crohn's disease	0.000686	0.015	CcSEcCtD
Pomalidomide—Hypocalcaemia—Mesalazine—Crohn's disease	0.000682	0.0149	CcSEcCtD
Pomalidomide—Embolism venous—Prednisone—Crohn's disease	0.000655	0.0143	CcSEcCtD
Pomalidomide—Thalidomide—TNF—Crohn's disease	0.000647	0.0959	CrCbGaD
Pomalidomide—Lymphopenia—Prednisone—Crohn's disease	0.000646	0.0141	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Mesalazine—Crohn's disease	0.000632	0.0138	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.000609	0.0133	CcSEcCtD
Pomalidomide—Neuropathy—Mesalazine—Crohn's disease	0.000587	0.0128	CcSEcCtD
Pomalidomide—Febrile neutropenia—Prednisone—Crohn's disease	0.000549	0.012	CcSEcCtD
Pomalidomide—Embolism—Prednisone—Crohn's disease	0.000515	0.0112	CcSEcCtD
Pomalidomide—Lenalidomide—PTGS2—Crohn's disease	0.000513	0.076	CrCbGaD
Pomalidomide—Malnutrition—Mercaptopurine—Crohn's disease	0.000503	0.011	CcSEcCtD
Pomalidomide—TNF—Overview of nanoparticle effects—CRP—Crohn's disease	0.000497	0.00945	CbGpPWpGaD
Pomalidomide—TNF—TNF receptor signaling pathway —TNFRSF1B—Crohn's disease	0.000481	0.00915	CbGpPWpGaD
Pomalidomide—Atrial fibrillation—Mesalazine—Crohn's disease	0.000479	0.0104	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—IL12B—Crohn's disease	0.000474	0.00902	CbGpPWpGaD
Pomalidomide—Anaemia—Mercaptopurine—Crohn's disease	0.000465	0.0101	CcSEcCtD
Pomalidomide—TNF—IL27-mediated signaling events—IL18—Crohn's disease	0.000462	0.00878	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—GPX4—Crohn's disease	0.000457	0.0087	CbGpPWpGaD
Pomalidomide—Leukopenia—Mercaptopurine—Crohn's disease	0.00045	0.00982	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL10—Crohn's disease	0.000446	0.00849	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—MPO—Crohn's disease	0.000429	0.00816	CbGpPWpGaD
Pomalidomide—Arthralgia—Mercaptopurine—Crohn's disease	0.000428	0.00934	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—PPP5C—Crohn's disease	0.000428	0.00815	CbGpPWpGaD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000425	0.00928	CcSEcCtD
Pomalidomide—Blood creatinine increased—Mesalazine—Crohn's disease	0.000425	0.00926	CcSEcCtD
Pomalidomide—Dry skin—Mesalazine—Crohn's disease	0.000416	0.00906	CcSEcCtD
Pomalidomide—Breast disorder—Mesalazine—Crohn's disease	0.00041	0.00894	CcSEcCtD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—RIPK2—Crohn's disease	0.000409	0.00778	CbGpPWpGaD
Pomalidomide—Pancytopenia—Azathioprine—Crohn's disease	0.000409	0.00891	CcSEcCtD
Pomalidomide—Nasopharyngitis—Mesalazine—Crohn's disease	0.000406	0.00884	CcSEcCtD
Pomalidomide—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000402	0.00877	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.0004	0.00872	CcSEcCtD
Pomalidomide—Skin disorder—Mercaptopurine—Crohn's disease	0.000399	0.0087	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL12B—Crohn's disease	0.000398	0.00758	CbGpPWpGaD
Pomalidomide—Pneumonia—Azathioprine—Crohn's disease	0.000386	0.00841	CcSEcCtD
Pomalidomide—Infestation NOS—Azathioprine—Crohn's disease	0.000384	0.00837	CcSEcCtD
Pomalidomide—Infestation—Azathioprine—Crohn's disease	0.000384	0.00837	CcSEcCtD
Pomalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—Crohn's disease	0.000379	0.00721	CbGpPWpGaD
Pomalidomide—Bronchitis—Mesalazine—Crohn's disease	0.000377	0.00822	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000374	0.00816	CcSEcCtD
Pomalidomide—Pancytopenia—Mesalazine—Crohn's disease	0.000372	0.00812	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CREM—Crohn's disease	0.000371	0.00705	CbGpPWpGaD
Pomalidomide—Neutropenia—Mesalazine—Crohn's disease	0.000367	0.00799	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000364	0.00794	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—GPX4—Crohn's disease	0.000363	0.00691	CbGpPWpGaD
Pomalidomide—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000363	0.00791	CcSEcCtD
Pomalidomide—Decreased appetite—Mercaptopurine—Crohn's disease	0.000357	0.00778	CcSEcCtD
Pomalidomide—Weight increased—Mesalazine—Crohn's disease	0.000357	0.00778	CcSEcCtD
Pomalidomide—Weight decreased—Mesalazine—Crohn's disease	0.000355	0.00773	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000355	0.00773	CcSEcCtD
Pomalidomide—PTGS2—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000353	0.00672	CbGpPWpGaD
Pomalidomide—Pneumonia—Mesalazine—Crohn's disease	0.000352	0.00766	CcSEcCtD
Pomalidomide—TNF—TNF receptor signaling pathway —TAB1—Crohn's disease	0.000351	0.00667	CbGpPWpGaD
Pomalidomide—Infestation NOS—Mesalazine—Crohn's disease	0.00035	0.00762	CcSEcCtD
Pomalidomide—Infestation—Mesalazine—Crohn's disease	0.00035	0.00762	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—MPO—Crohn's disease	0.000349	0.00664	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IL18—Crohn's disease	0.000348	0.00662	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—Crohn's disease	0.000347	0.0066	CbGpPWpGaD
Pomalidomide—Renal failure—Mesalazine—Crohn's disease	0.000344	0.00749	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000343	0.00747	CcSEcCtD
Pomalidomide—Urinary tract infection—Mesalazine—Crohn's disease	0.00034	0.00741	CcSEcCtD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—RIPK2—Crohn's disease	0.000339	0.00646	CbGpPWpGaD
Pomalidomide—TNF—Overview of nanoparticle effects—PTGS2—Crohn's disease	0.000333	0.00634	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—Crohn's disease	0.000332	0.00631	CbGpPWpGaD
Pomalidomide—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000331	0.00721	CcSEcCtD
Pomalidomide—Epistaxis—Mesalazine—Crohn's disease	0.00033	0.00719	CcSEcCtD
Pomalidomide—Body temperature increased—Mercaptopurine—Crohn's disease	0.000325	0.00708	CcSEcCtD
Pomalidomide—TNF—Overview of nanoparticle effects—CXCL8—Crohn's disease	0.000323	0.00615	CbGpPWpGaD
Pomalidomide—Mediastinal disorder—Azathioprine—Crohn's disease	0.00031	0.00677	CcSEcCtD
Pomalidomide—Neuropathy—Prednisone—Crohn's disease	0.00031	0.00677	CcSEcCtD
Pomalidomide—Urinary tract disorder—Mesalazine—Crohn's disease	0.00031	0.00676	CcSEcCtD
Pomalidomide—Oedema peripheral—Mesalazine—Crohn's disease	0.000309	0.00674	CcSEcCtD
Pomalidomide—Chills—Azathioprine—Crohn's disease	0.000309	0.00674	CcSEcCtD
Pomalidomide—Connective tissue disorder—Mesalazine—Crohn's disease	0.000308	0.00672	CcSEcCtD
Pomalidomide—Urethral disorder—Mesalazine—Crohn's disease	0.000308	0.00671	CcSEcCtD
Pomalidomide—Thalidomide—PTGS2—Crohn's disease	0.000307	0.0455	CrCbGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—CRP—Crohn's disease	0.000307	0.00584	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000303	0.0066	CcSEcCtD
Pomalidomide—TNF—amb2 Integrin signaling—ICAM1—Crohn's disease	0.000301	0.00572	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TNFRSF1B—Crohn's disease	0.000297	0.00565	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MST1—Crohn's disease	0.000293	0.00557	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Mesalazine—Crohn's disease	0.000291	0.00635	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—LRRK2—Crohn's disease	0.000289	0.00551	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—TYK2—Crohn's disease	0.000289	0.00549	CbGpPWpGaD
Pomalidomide—Sepsis—Prednisone—Crohn's disease	0.000287	0.00625	CcSEcCtD
Pomalidomide—Angiopathy—Mesalazine—Crohn's disease	0.000285	0.00621	CcSEcCtD
Pomalidomide—Mediastinal disorder—Mesalazine—Crohn's disease	0.000283	0.00617	CcSEcCtD
Pomalidomide—Chills—Mesalazine—Crohn's disease	0.000282	0.00614	CcSEcCtD
Pomalidomide—Diarrhoea—Mercaptopurine—Crohn's disease	0.000281	0.00613	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL17A—Crohn's disease	0.000278	0.00529	CbGpPWpGaD
Pomalidomide—TNF—EBV LMP1 signaling—CXCL8—Crohn's disease	0.000277	0.00527	CbGpPWpGaD
Pomalidomide—Anaemia—Azathioprine—Crohn's disease	0.000277	0.00604	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—MPO—Crohn's disease	0.000277	0.00527	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—TNFRSF1B—Crohn's disease	0.000276	0.00525	CbGpPWpGaD
Pomalidomide—TNF—Cellular roles of Anthrax toxin—IL1B—Crohn's disease	0.000276	0.00524	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—JAK2—Crohn's disease	0.000275	0.00524	CbGpPWpGaD
Pomalidomide—Mental disorder—Mesalazine—Crohn's disease	0.000275	0.00599	CcSEcCtD
Pomalidomide—TNF—IL27-mediated signaling events—IFNG—Crohn's disease	0.00027	0.00514	CbGpPWpGaD
Pomalidomide—Leukopenia—Azathioprine—Crohn's disease	0.000268	0.00585	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Prednisone—Crohn's disease	0.000265	0.00577	CcSEcCtD
Pomalidomide—Back pain—Mesalazine—Crohn's disease	0.000264	0.00576	CcSEcCtD
Pomalidomide—Muscle spasms—Mesalazine—Crohn's disease	0.000263	0.00573	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IFNG—Crohn's disease	0.000262	0.00499	CbGpPWpGaD
Pomalidomide—Vomiting—Mercaptopurine—Crohn's disease	0.000261	0.00569	CcSEcCtD
Pomalidomide—Rash—Mercaptopurine—Crohn's disease	0.000259	0.00565	CcSEcCtD
Pomalidomide—Dermatitis—Mercaptopurine—Crohn's disease	0.000259	0.00564	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL12B—Crohn's disease	0.000258	0.00492	CbGpPWpGaD
Pomalidomide—Tremor—Mesalazine—Crohn's disease	0.000256	0.00558	CcSEcCtD
Pomalidomide—Arthralgia—Azathioprine—Crohn's disease	0.000255	0.00557	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000254	0.00553	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CD4—Crohn's disease	0.000253	0.00482	CbGpPWpGaD
Pomalidomide—Anaemia—Mesalazine—Crohn's disease	0.000252	0.0055	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—SMAD3—Crohn's disease	0.000247	0.00469	CbGpPWpGaD
Pomalidomide—Vertigo—Mesalazine—Crohn's disease	0.000245	0.00535	CcSEcCtD
Pomalidomide—Leukopenia—Mesalazine—Crohn's disease	0.000244	0.00533	CcSEcCtD
Pomalidomide—Nausea—Mercaptopurine—Crohn's disease	0.000244	0.00532	CcSEcCtD
Pomalidomide—Infection—Azathioprine—Crohn's disease	0.000243	0.0053	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Crohn's disease	0.000243	0.00462	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL1B—Crohn's disease	0.000241	0.00459	CbGpPWpGaD
Pomalidomide—Thrombocytopenia—Azathioprine—Crohn's disease	0.00024	0.00522	CcSEcCtD
Pomalidomide—Cough—Mesalazine—Crohn's disease	0.000238	0.0052	CcSEcCtD
Pomalidomide—Skin disorder—Azathioprine—Crohn's disease	0.000238	0.00518	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL1B—Crohn's disease	0.000234	0.00445	CbGpPWpGaD
Pomalidomide—Arthralgia—Mesalazine—Crohn's disease	0.000233	0.00507	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—Crohn's disease	0.000232	0.00442	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—LRRK2—Crohn's disease	0.000232	0.00441	CbGpPWpGaD
Pomalidomide—Anxiety—Mesalazine—Crohn's disease	0.000232	0.00505	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000231	0.00504	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—CRP—Crohn's disease	0.000225	0.00429	CbGpPWpGaD
Pomalidomide—Confusional state—Mesalazine—Crohn's disease	0.000225	0.0049	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—GPX4—Crohn's disease	0.000225	0.00428	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000223	0.00486	CcSEcCtD
Pomalidomide—Infection—Mesalazine—Crohn's disease	0.000221	0.00483	CcSEcCtD
Pomalidomide—Dry skin—Prednisone—Crohn's disease	0.00022	0.0048	CcSEcCtD
Pomalidomide—Nervous system disorder—Mesalazine—Crohn's disease	0.000219	0.00477	CcSEcCtD
Pomalidomide—Hypokalaemia—Prednisone—Crohn's disease	0.000218	0.00476	CcSEcCtD
Pomalidomide—Thrombocytopenia—Mesalazine—Crohn's disease	0.000218	0.00476	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—TYK2—Crohn's disease	0.000218	0.00414	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TAB1—Crohn's disease	0.000217	0.00412	CbGpPWpGaD
Pomalidomide—Skin disorder—Mesalazine—Crohn's disease	0.000217	0.00472	CcSEcCtD
Pomalidomide—Hyperhidrosis—Mesalazine—Crohn's disease	0.000215	0.0047	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—Crohn's disease	0.000214	0.00408	CbGpPWpGaD
Pomalidomide—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000212	0.00461	CcSEcCtD
Pomalidomide—Muscular weakness—Prednisone—Crohn's disease	0.000212	0.00461	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000211	0.00461	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL12B—Crohn's disease	0.000211	0.00401	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—JAK2—Crohn's disease	0.000208	0.00395	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—ICAM1—Crohn's disease	0.000207	0.00394	CbGpPWpGaD
Pomalidomide—TNF—Monoamine Transport—IL1B—Crohn's disease	0.000204	0.00389	CbGpPWpGaD
Pomalidomide—TNF—IL23-mediated signaling events—IFNG—Crohn's disease	0.000204	0.00388	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000203	0.00443	CcSEcCtD
Pomalidomide—TNF—IL27-mediated signaling events—STAT3—Crohn's disease	0.000202	0.00385	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Azathioprine—Crohn's disease	0.000202	0.0044	CcSEcCtD
Pomalidomide—Insomnia—Mesalazine—Crohn's disease	0.000202	0.0044	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—TAB1—Crohn's disease	0.000201	0.00383	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—GPX4—Crohn's disease	0.0002	0.0038	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—Crohn's disease	0.0002	0.0038	CbGpPWpGaD
Pomalidomide—Dyspnoea—Mesalazine—Crohn's disease	0.000199	0.00433	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—CD4—Crohn's disease	0.000197	0.00375	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2RA—Crohn's disease	0.000194	0.0037	CbGpPWpGaD
Pomalidomide—Neutropenia—Prednisone—Crohn's disease	0.000194	0.00423	CcSEcCtD
Pomalidomide—Decreased appetite—Mesalazine—Crohn's disease	0.000194	0.00423	CcSEcCtD
Pomalidomide—Body temperature increased—Azathioprine—Crohn's disease	0.000193	0.00422	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000192	0.0042	CcSEcCtD
Pomalidomide—Fatigue—Mesalazine—Crohn's disease	0.000192	0.00419	CcSEcCtD
Pomalidomide—TNF—lymph node—Crohn's disease	0.000191	0.127	CbGeAlD
Pomalidomide—Pain—Mesalazine—Crohn's disease	0.000191	0.00416	CcSEcCtD
Pomalidomide—Constipation—Mesalazine—Crohn's disease	0.000191	0.00416	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL10—Crohn's disease	0.000189	0.0036	CbGpPWpGaD
Pomalidomide—Weight increased—Prednisone—Crohn's disease	0.000189	0.00412	CcSEcCtD
Pomalidomide—Weight decreased—Prednisone—Crohn's disease	0.000188	0.00409	CcSEcCtD
Pomalidomide—Hyperglycaemia—Prednisone—Crohn's disease	0.000187	0.00408	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—TAB1—Crohn's disease	0.000185	0.00353	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Mesalazine—Crohn's disease	0.000184	0.00401	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—CRP—Crohn's disease	0.000183	0.00349	CbGpPWpGaD
Pomalidomide—CRBN—mammalian vulva—Crohn's disease	0.000182	0.121	CbGeAlD
Pomalidomide—TNF—IL23-mediated signaling events—IL1B—Crohn's disease	0.000182	0.00346	CbGpPWpGaD
Pomalidomide—TNF—Overview of nanoparticle effects—IL6—Crohn's disease	0.000181	0.00345	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Prednisone—Crohn's disease	0.000181	0.00395	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MST1—Crohn's disease	0.000181	0.00345	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Azathioprine—Crohn's disease	0.00018	0.00393	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—MPO—Crohn's disease	0.000178	0.00338	CbGpPWpGaD
Pomalidomide—Body temperature increased—Mesalazine—Crohn's disease	0.000176	0.00384	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—ALB—Crohn's disease	0.000173	0.00329	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—MPO—Crohn's disease	0.000171	0.00326	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	0.000171	0.00326	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—ICAM1—Crohn's disease	0.000169	0.00321	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IL2RA—Crohn's disease	0.000168	0.0032	CbGpPWpGaD
Pomalidomide—Diarrhoea—Azathioprine—Crohn's disease	0.000167	0.00365	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL12B—Crohn's disease	0.000164	0.00313	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Mesalazine—Crohn's disease	0.000164	0.00358	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	0.000164	0.00312	CbGpPWpGaD
Pomalidomide—Connective tissue disorder—Prednisone—Crohn's disease	0.000163	0.00356	CcSEcCtD
Pomalidomide—Dizziness—Azathioprine—Crohn's disease	0.000162	0.00353	CcSEcCtD
Pomalidomide—CRBN—lymphoid tissue—Crohn's disease	0.000161	0.108	CbGeAlD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—IL6—Crohn's disease	0.000161	0.00307	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Crohn's disease	0.00016	0.00305	CbGpPWpGaD
Pomalidomide—Asthenia—Mesalazine—Crohn's disease	0.00016	0.00349	CcSEcCtD
Pomalidomide—CRBN—digestive system—Crohn's disease	0.00016	0.107	CbGeAlD
Pomalidomide—Pruritus—Mesalazine—Crohn's disease	0.000158	0.00344	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—IFNG—Crohn's disease	0.000158	0.003	CbGpPWpGaD
Pomalidomide—Vomiting—Azathioprine—Crohn's disease	0.000156	0.00339	CcSEcCtD
Pomalidomide—Rash—Azathioprine—Crohn's disease	0.000154	0.00336	CcSEcCtD
Pomalidomide—Dermatitis—Azathioprine—Crohn's disease	0.000154	0.00336	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—Crohn's disease	0.000154	0.00292	CbGpPWpGaD
Pomalidomide—Headache—Azathioprine—Crohn's disease	0.000153	0.00334	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—Crohn's disease	0.000153	0.00291	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	0.000153	0.00291	CbGpPWpGaD
Pomalidomide—Diarrhoea—Mesalazine—Crohn's disease	0.000153	0.00333	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—STAT3—Crohn's disease	0.000152	0.0029	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—IFNG—Crohn's disease	0.000151	0.00287	CbGpPWpGaD
Pomalidomide—Angiopathy—Prednisone—Crohn's disease	0.000151	0.00328	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Crohn's disease	0.00015	0.00286	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—Crohn's disease	0.000149	0.00283	CbGpPWpGaD
Pomalidomide—Dizziness—Mesalazine—Crohn's disease	0.000147	0.00321	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—CRP—Crohn's disease	0.000146	0.00277	CbGpPWpGaD
Pomalidomide—Mental disorder—Prednisone—Crohn's disease	0.000145	0.00317	CcSEcCtD
Pomalidomide—Nausea—Azathioprine—Crohn's disease	0.000145	0.00317	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TAB1—Crohn's disease	0.000145	0.00275	CbGpPWpGaD
Pomalidomide—Malnutrition—Prednisone—Crohn's disease	0.000145	0.00315	CcSEcCtD
Pomalidomide—Vomiting—Mesalazine—Crohn's disease	0.000142	0.00309	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—SOCS1—Crohn's disease	0.000141	0.00269	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—IL6—Crohn's disease	0.000141	0.00269	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL1B—Crohn's disease	0.000141	0.00268	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—ALB—Crohn's disease	0.000141	0.00267	CbGpPWpGaD
Pomalidomide—Rash—Mesalazine—Crohn's disease	0.000141	0.00306	CcSEcCtD
Pomalidomide—Dermatitis—Mesalazine—Crohn's disease	0.00014	0.00306	CcSEcCtD
Pomalidomide—Headache—Mesalazine—Crohn's disease	0.00014	0.00304	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—Crohn's disease	0.000139	0.00265	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—Crohn's disease	0.000139	0.00265	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL6—Crohn's disease	0.000137	0.00261	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—SOCS1—Crohn's disease	0.000134	0.00255	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—TAB1—Crohn's disease	0.000134	0.00255	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—ICAM1—Crohn's disease	0.000134	0.00255	CbGpPWpGaD
Pomalidomide—Anaemia—Prednisone—Crohn's disease	0.000134	0.00291	CcSEcCtD
Pomalidomide—Nausea—Mesalazine—Crohn's disease	0.000132	0.00289	CcSEcCtD
Pomalidomide—Vertigo—Prednisone—Crohn's disease	0.00013	0.00283	CcSEcCtD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MST1—Crohn's disease	0.000128	0.00244	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IFNG—Crohn's disease	0.000128	0.00244	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—Crohn's disease	0.000128	0.00244	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—RASGRP1—Crohn's disease	0.000127	0.00242	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TAB1—Crohn's disease	0.000124	0.00237	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR4—Crohn's disease	0.000124	0.00236	CbGpPWpGaD
Pomalidomide—CYP1A2—Estrogen Receptor Pathway—STAT3—Crohn's disease	0.000123	0.00234	CbGpPWpGaD
Pomalidomide—Arthralgia—Prednisone—Crohn's disease	0.000123	0.00268	CcSEcCtD
Pomalidomide—Anxiety—Prednisone—Crohn's disease	0.000123	0.00267	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000122	0.00266	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—SMAD3—Crohn's disease	0.000122	0.00232	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL17A—Crohn's disease	0.000122	0.00232	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—IL6—Crohn's disease	0.00012	0.00228	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	0.000119	0.00226	CbGpPWpGaD
Pomalidomide—Infection—Prednisone—Crohn's disease	0.000117	0.00255	CcSEcCtD
Pomalidomide—Nervous system disorder—Prednisone—Crohn's disease	0.000116	0.00252	CcSEcCtD
Pomalidomide—Skin disorder—Prednisone—Crohn's disease	0.000115	0.0025	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—IL1B—Crohn's disease	0.000114	0.00218	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Prednisone—Crohn's disease	0.000114	0.00249	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL12B—Crohn's disease	0.000113	0.00216	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—STAT3—Crohn's disease	0.000113	0.00214	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—IL6—Crohn's disease	0.000112	0.00214	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—ALB—Crohn's disease	0.000112	0.00213	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—IFNG—Crohn's disease	0.000111	0.00211	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TLR4—Crohn's disease	0.00011	0.0021	CbGpPWpGaD
Pomalidomide—PTGS2—gall bladder—Crohn's disease	0.00011	0.0737	CbGeAlD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—Crohn's disease	0.00011	0.00209	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000107	0.00234	CcSEcCtD
Pomalidomide—Insomnia—Prednisone—Crohn's disease	0.000107	0.00233	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—IL6—Crohn's disease	0.000106	0.00203	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—ICAM1—Crohn's disease	0.000106	0.00202	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CXCL8—Crohn's disease	0.000103	0.00197	CbGpPWpGaD
Pomalidomide—Decreased appetite—Prednisone—Crohn's disease	0.000103	0.00224	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IFNG—Crohn's disease	0.000102	0.00194	CbGpPWpGaD
Pomalidomide—Fatigue—Prednisone—Crohn's disease	0.000102	0.00222	CcSEcCtD
Pomalidomide—Constipation—Prednisone—Crohn's disease	0.000101	0.0022	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL1B—Crohn's disease	9.91e-05	0.00189	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—IL1B—Crohn's disease	9.91e-05	0.00189	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Crohn's disease	9.91e-05	0.00189	CbGpPWpGaD
Pomalidomide—PTGS2—mouth—Crohn's disease	9.81e-05	0.0655	CbGeAlD
Pomalidomide—TNF—Selenium Micronutrient Network—PTGS2—Crohn's disease	9.77e-05	0.00186	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Prednisone—Crohn's disease	9.72e-05	0.00212	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR4—Crohn's disease	9.69e-05	0.00184	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—IL6—Crohn's disease	9.62e-05	0.00183	CbGpPWpGaD
Pomalidomide—Body temperature increased—Prednisone—Crohn's disease	9.32e-05	0.00203	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—Crohn's disease	9.21e-05	0.00175	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—SMAD3—Crohn's disease	9.21e-05	0.00175	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—STAT3—Crohn's disease	9.15e-05	0.00174	CbGpPWpGaD
Pomalidomide—CRBN—lymph node—Crohn's disease	9.11e-05	0.0608	CbGeAlD
Pomalidomide—TNF—Selenium Micronutrient Network—IL1B—Crohn's disease	9.09e-05	0.00173	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CRP—Crohn's disease	9.01e-05	0.00171	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Prednisone—Crohn's disease	8.69e-05	0.00189	CcSEcCtD
Pomalidomide—Asthenia—Prednisone—Crohn's disease	8.46e-05	0.00184	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CXCL8—Crohn's disease	8.42e-05	0.0016	CbGpPWpGaD
Pomalidomide—Pruritus—Prednisone—Crohn's disease	8.34e-05	0.00182	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ICAM1—Crohn's disease	8.28e-05	0.00158	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL10—Crohn's disease	8.28e-05	0.00158	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL6—Crohn's disease	8.24e-05	0.00157	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	8.14e-05	0.00155	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—Crohn's disease	8.08e-05	0.00154	CbGpPWpGaD
Pomalidomide—Diarrhoea—Prednisone—Crohn's disease	8.07e-05	0.00176	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—IFNG—Crohn's disease	8.06e-05	0.00153	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—STAT3—Crohn's disease	7.91e-05	0.00151	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisone—Crohn's disease	7.8e-05	0.0017	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—PTGS2—Crohn's disease	7.73e-05	0.00147	CbGpPWpGaD
Pomalidomide—Vomiting—Prednisone—Crohn's disease	7.5e-05	0.00163	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CXCL8—Crohn's disease	7.5e-05	0.00143	CbGpPWpGaD
Pomalidomide—Rash—Prednisone—Crohn's disease	7.44e-05	0.00162	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—Crohn's disease	7.43e-05	0.00162	CcSEcCtD
Pomalidomide—Headache—Prednisone—Crohn's disease	7.39e-05	0.00161	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL2RA—Crohn's disease	7.38e-05	0.0014	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GPX4—Crohn's disease	7.34e-05	0.0014	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	7.34e-05	0.0014	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL1B—Crohn's disease	7.19e-05	0.00137	CbGpPWpGaD
Pomalidomide—Nausea—Prednisone—Crohn's disease	7.01e-05	0.00153	CcSEcCtD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	6.92e-05	0.00132	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ALB—Crohn's disease	6.91e-05	0.00131	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	6.86e-05	0.0013	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TLR4—Crohn's disease	6.83e-05	0.0013	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL6—Crohn's disease	6.7e-05	0.00127	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL8—Crohn's disease	6.57e-05	0.00125	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—ICAM1—Crohn's disease	6.55e-05	0.00125	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Crohn's disease	6.41e-05	0.00122	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD4—Crohn's disease	6.32e-05	0.0012	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—Crohn's disease	6.31e-05	0.0012	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IFNG—Crohn's disease	6.3e-05	0.0012	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	6e-05	0.00114	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	5.99e-05	0.00114	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1B—Crohn's disease	5.75e-05	0.00109	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	5.75e-05	0.00109	CbGpPWpGaD
Pomalidomide—PTGS2—epithelium—Crohn's disease	5.71e-05	0.0381	CbGeAlD
Pomalidomide—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	5.66e-05	0.00108	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL1B—Crohn's disease	5.62e-05	0.00107	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—STAT3—Crohn's disease	5.58e-05	0.00106	CbGpPWpGaD
Pomalidomide—PTGS2—smooth muscle tissue—Crohn's disease	5.5e-05	0.0367	CbGeAlD
Pomalidomide—PTGS2—skin of body—Crohn's disease	5.43e-05	0.0363	CbGeAlD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1B—Crohn's disease	5.42e-05	0.00103	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	5.39e-05	0.00103	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—Crohn's disease	5.38e-05	0.00102	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	5.35e-05	0.00102	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IL6—Crohn's disease	5.32e-05	0.00101	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	5.26e-05	0.001	CbGpPWpGaD
Pomalidomide—CYP1A2—digestive system—Crohn's disease	5.24e-05	0.035	CbGeAlD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	5.2e-05	0.00099	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—IL6—Crohn's disease	5.14e-05	0.000977	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	5.05e-05	0.000961	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IFNG—Crohn's disease	4.99e-05	0.000948	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IFNG—Crohn's disease	4.87e-05	0.000927	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—Crohn's disease	4.73e-05	0.0009	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	4.66e-05	0.000887	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	4.66e-05	0.000887	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL8—Crohn's disease	4.64e-05	0.000882	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	4.61e-05	0.000876	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CXCL8—Crohn's disease	4.53e-05	0.000862	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1B—Crohn's disease	4.45e-05	0.000846	CbGpPWpGaD
Pomalidomide—PTGS2—lymphoid tissue—Crohn's disease	4.4e-05	0.0294	CbGeAlD
Pomalidomide—ABCB1—Allograft Rejection—IL1B—Crohn's disease	4.35e-05	0.000827	CbGpPWpGaD
Pomalidomide—PTGS2—digestive system—Crohn's disease	4.34e-05	0.029	CbGeAlD
Pomalidomide—TNF—Spinal Cord Injury—IL6—Crohn's disease	4.21e-05	0.000801	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—SMAD3—Crohn's disease	4.2e-05	0.000798	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—Crohn's disease	4.08e-05	0.000776	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	3.92e-05	0.000745	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IL6—Crohn's disease	3.9e-05	0.000741	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	3.88e-05	0.000738	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	3.88e-05	0.000738	CbGpPWpGaD
Pomalidomide—CYP3A4—digestive system—Crohn's disease	3.8e-05	0.0253	CbGeAlD
Pomalidomide—PTGS2—Disease—RSPO3—Crohn's disease	3.78e-05	0.00072	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—Crohn's disease	3.69e-05	0.000703	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PLA2G4F—Crohn's disease	3.62e-05	0.00069	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SEL1L—Crohn's disease	3.59e-05	0.000682	CbGpPWpGaD
Pomalidomide—ABCB1—epithelium—Crohn's disease	3.53e-05	0.0236	CbGeAlD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—Crohn's disease	3.37e-05	0.000641	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—Crohn's disease	3.29e-05	0.000626	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—GCKR—Crohn's disease	3.29e-05	0.000625	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—Crohn's disease	3.23e-05	0.000614	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LTF—Crohn's disease	3.22e-05	0.000612	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—Crohn's disease	3.15e-05	0.0006	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTMR3—Crohn's disease	3.08e-05	0.000586	CbGpPWpGaD
Pomalidomide—ABCB1—mammalian vulva—Crohn's disease	3.06e-05	0.0205	CbGeAlD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	3.05e-05	0.00058	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	2.91e-05	0.000553	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	2.86e-05	0.000544	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TYK2—Crohn's disease	2.74e-05	0.000521	CbGpPWpGaD
Pomalidomide—ABCB1—lymphoid tissue—Crohn's disease	2.72e-05	0.0182	CbGeAlD
Pomalidomide—ABCB1—digestive system—Crohn's disease	2.69e-05	0.0179	CbGeAlD
Pomalidomide—TNF—Developmental Biology—JAK2—Crohn's disease	2.61e-05	0.000497	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—Crohn's disease	2.6e-05	0.000495	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GCKR—Crohn's disease	2.59e-05	0.000493	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PLA2G4F—Crohn's disease	2.57e-05	0.000489	CbGpPWpGaD
Pomalidomide—PTGS2—lymph node—Crohn's disease	2.48e-05	0.0166	CbGeAlD
Pomalidomide—PTGS2—Metabolism—FADS1—Crohn's disease	2.4e-05	0.000457	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	2.3e-05	0.000438	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SLC11A1—Crohn's disease	2.29e-05	0.000436	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GPX4—Crohn's disease	2.25e-05	0.000428	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.2e-05	0.000418	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTMR3—Crohn's disease	2.18e-05	0.000416	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GCKR—Crohn's disease	2.17e-05	0.000413	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	2.05e-05	0.00039	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RBX1—Crohn's disease	1.97e-05	0.000374	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HSPA1B—Crohn's disease	1.97e-05	0.000374	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—Crohn's disease	1.92e-05	0.000365	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTMR3—Crohn's disease	1.74e-05	0.000332	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—UBE2D1—Crohn's disease	1.72e-05	0.000328	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—FADS1—Crohn's disease	1.7e-05	0.000324	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GPX4—Crohn's disease	1.59e-05	0.000303	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	1.58e-05	0.000301	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	1.56e-05	0.000296	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.55e-05	0.000295	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GCKR—Crohn's disease	1.54e-05	0.000293	CbGpPWpGaD
Pomalidomide—ABCB1—lymph node—Crohn's disease	1.53e-05	0.0102	CbGeAlD
Pomalidomide—CYP1A2—Metabolism—FADS1—Crohn's disease	1.36e-05	0.000259	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTMR3—Crohn's disease	1.35e-05	0.000256	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—Crohn's disease	1.34e-05	0.000255	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GPX4—Crohn's disease	1.27e-05	0.000242	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SMAD3—Crohn's disease	1.23e-05	0.000235	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GCKR—Crohn's disease	1.23e-05	0.000234	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—FADS1—Crohn's disease	1.05e-05	0.0002	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.05e-05	0.000199	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GPX4—Crohn's disease	9.82e-06	0.000187	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GCKR—Crohn's disease	9.48e-06	0.00018	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	8.78e-06	0.000167	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TYK2—Crohn's disease	8.04e-06	0.000153	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	7.68e-06	0.000146	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—JAK2—Crohn's disease	7.67e-06	0.000146	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—Crohn's disease	7.27e-06	0.000138	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—Crohn's disease	6.91e-06	0.000131	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—Crohn's disease	5.63e-06	0.000107	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—Crohn's disease	4.9e-06	9.32e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—Crohn's disease	4.29e-06	8.15e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—Crohn's disease	3.93e-06	7.48e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—Crohn's disease	3.91e-06	7.44e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—Crohn's disease	3.42e-06	6.51e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—Crohn's disease	3.02e-06	5.74e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—Crohn's disease	2.64e-06	5.02e-05	CbGpPWpGaD
